Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 157

1.

Conventionally fractionated stereotactic radiotherapy (CFRT) in combination with dose-dense temozolomide (TMZ) in relapsed malignant glioma: A case report.

Qie S, Yuan L, Shi HY, Zhang X, Li Y.

Medicine (Baltimore). 2019 Jan;98(1):e13869. doi: 10.1097/MD.0000000000013869.

2.

Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas.

Combs SE, Bischof M, Welzel T, Hof H, Oertel S, Debus J, Schulz-Ertner D.

J Neurooncol. 2008 Sep;89(2):205-10. doi: 10.1007/s11060-008-9607-4. Epub 2008 May 7.

PMID:
18461281
3.

Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.

Ishikawa E, Muragaki Y, Yamamoto T, Maruyama T, Tsuboi K, Ikuta S, Hashimoto K, Uemae Y, Ishihara T, Matsuda M, Matsutani M, Karasawa K, Nakazato Y, Abe T, Ohno T, Matsumura A.

J Neurosurg. 2014 Sep;121(3):543-53. doi: 10.3171/2014.5.JNS132392. Epub 2014 Jul 4.

PMID:
24995786
4.

Outcome of salvage treatment for recurrent glioblastoma.

Kim HR, Kim KH, Kong DS, Seol HJ, Nam DH, Lim DH, Lee JI.

J Clin Neurosci. 2015 Mar;22(3):468-73. doi: 10.1016/j.jocn.2014.09.018. Epub 2015 Jan 13.

PMID:
25595963
5.

Fractionated stereotactic reirradiation and concurrent temozolomide in patients with recurrent glioblastoma.

Minniti G, Armosini V, Salvati M, Lanzetta G, Caporello P, Mei M, Osti MF, Maurizi RE.

J Neurooncol. 2011 Jul;103(3):683-91. doi: 10.1007/s11060-010-0446-8. Epub 2010 Nov 5.

PMID:
21052773
6.

Efficacy and toxicity of CyberKnife re-irradiation and "dose dense" temozolomide for recurrent gliomas.

Conti A, Pontoriero A, Arpa D, Siragusa C, Tomasello C, Romanelli P, Cardali S, Granata F, De Renzis C, Tomasello F.

Acta Neurochir (Wien). 2012 Feb;154(2):203-9. doi: 10.1007/s00701-011-1184-1. Epub 2011 Oct 9.

PMID:
21984132
7.

Hypofractionated stereotactic radiotherapy and continuous low-dose temozolomide in patients with recurrent or progressive malignant gliomas.

Minniti G, Scaringi C, De Sanctis V, Lanzetta G, Falco T, Di Stefano D, Esposito V, Enrici RM.

J Neurooncol. 2013 Jan;111(2):187-94. doi: 10.1007/s11060-012-0999-9. Epub 2012 Nov 6.

PMID:
23129347
8.

Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era.

Paravati AJ, Heron DE, Landsittel D, Flickinger JC, Mintz A, Chen YF, Huq MS.

J Neurooncol. 2011 Aug;104(1):339-49. doi: 10.1007/s11060-010-0499-8. Epub 2010 Dec 22.

9.

Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.

Jastaniyah N, Murtha A, Pervez N, Le D, Roa W, Patel S, Mackenzie M, Fulton D, Field C, Ghosh S, Fallone G, Abdulkarim B.

Radiat Oncol. 2013 Feb 20;8:38. doi: 10.1186/1748-717X-8-38.

11.

Radiotherapy plus temozolomide in elderly patients with glioblastoma: a "real-life" report.

Biau J, Chautard E, De Schlichting E, Dupic G, Pereira B, Fogli A, Müller-Barthélémy M, Dalloz P, Khalil T, Dillies AF, Durando X, Godfraind C, Verrelle P.

Radiat Oncol. 2017 Dec 6;12(1):197. doi: 10.1186/s13014-017-0929-2.

12.

Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.

Reddy K, Damek D, Gaspar LE, Ney D, Waziri A, Lillehei K, Stuhr K, Kavanagh BD, Chen C.

Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):655-60. doi: 10.1016/j.ijrobp.2012.01.035. Epub 2012 Apr 5.

PMID:
22483738
13.

The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma.

Park CK, Lee SH, Kim TM, Choi SH, Park SH, Heo DS, Kim IH, Jung HW.

J Neurooncol. 2013 Apr;112(2):277-83. doi: 10.1007/s11060-013-1060-3. Epub 2013 Feb 2.

PMID:
23377829
14.

Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme.

Chen C, Damek D, Gaspar LE, Waziri A, Lillehei K, Kleinschmidt-DeMasters BK, Robischon M, Stuhr K, Rusthoven KE, Kavanagh BD.

Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):1066-74. doi: 10.1016/j.ijrobp.2010.07.021. Epub 2010 Oct 6.

PMID:
20932651
15.

Long-term follow-up results of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastoma multiforme patients. The importance of MRI information in survival: Single-center experience.

Lukács G, Tóth Z, Sipos D, Csima M, Hadjiev J, Bajzik G, Cselik Z, Semjén D, Repa I, Kovács Á.

Ideggyogy Sz. 2018 Mar 30;71(3-04):95-103. doi: 10.18071/isz.71.0095.

PMID:
29889468
16.

The effect of field strength on glioblastoma multiforme response in patients treated with the NovoTTF™-100A system.

Turner SG, Gergel T, Wu H, Lacroix M, Toms SA.

World J Surg Oncol. 2014 May 22;12:162. doi: 10.1186/1477-7819-12-162.

17.

Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma.

Zhu JJ, Demireva P, Kanner AA, Pannullo S, Mehdorn M, Avgeropoulos N, Salmaggi A, Silvani A, Goldlust S, David C, Benouaich-Amiel A; Zvi Ram on behalf of the EF-14 Trial Investigators.

J Neurooncol. 2017 Dec;135(3):545-552. doi: 10.1007/s11060-017-2601-y. Epub 2017 Aug 28.

18.

Craniospinal irradiation with concomitant and adjuvant temozolomide--a feasibility assessment of toxicity in patients with glioblastoma with a PNET component.

O'Leary B, Mandeville HC, Fersht N, Solda F, Mycroft J, Zacharoulis S, Vaidya S, Saran F.

J Neurooncol. 2016 Apr;127(2):295-302. doi: 10.1007/s11060-015-2033-5. Epub 2016 Feb 2.

PMID:
26842817
19.

Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.

Schiff D, Desjardins A, Cloughesy T, Mikkelsen T, Glantz M, Chamberlain MC, Reardon DA, Wen PY.

Cancer. 2016 Feb 15;122(4):582-7. doi: 10.1002/cncr.29798. Epub 2015 Nov 20.

20.

Single-arm phase II study of conformal radiation therapy and temozolomide plus fractionated stereotactic conformal boost in high-grade gliomas: final report.

Balducci M, Apicella G, Manfrida S, Mangiola A, Fiorentino A, Azario L, D'Agostino GR, Frascino V, Dinapoli N, Mantini G, Albanese A, de Bonis P, Chiesa S, Valentini V, Anile C, Cellini N.

Strahlenther Onkol. 2010 Oct;186(10):558-64. doi: 10.1007/s00066-010-2101-x. Epub 2010 Sep 30.

PMID:
20936460

Supplemental Content

Support Center